Renal outcomes of treatment with telmisartan in patients with stage 3–4 chronic kidney disease: A prospective, randomized, controlled trial (JINNAGA)

Mineaki Kitamura1*, Hideyuki Arai1,2*, Shinichi Abe1, Yuki Ota1, Kumiko Muta1, Akira Furusu3, Hiroshi Mukae4, Shigeru Kohno4 and Tomoya Nishino1

Abstract
Objectives: Although angiotensin II receptor blockers are effective for patients with chronic kidney disease, dose-dependent renoprotective effects of angiotensin II receptor blockers in patients with moderate to severe chronic kidney disease with non-nephrotic proteinuria are not known. Our aim was to elucidate the dose-dependent renoprotective effects of angiotensin II receptor blockers on such patients.
Methods: A multicenter, prospective, randomized trial was conducted from 2009 to 2014. Patients with non-nephrotic stage 3–4 chronic kidney disease were randomized for treatment with either 40 or 80 mg telmisartan and were observed for up to 104 weeks. Overall, 32 and 29 patients were allocated to the 40 and 80 mg telmisartan groups, respectively. The composite primary outcome was renal death, doubling of serum creatinine level, transition to stage 5 chronic kidney disease, and death from any cause. Secondary outcomes included the level of urinary proteins and changes in the estimated glomerular filtration rate.
Results: There was no difference in the primary outcome (p = 0.78) and eGFR (p = 0.53) between the two groups; however, after 24 weeks, urinary protein level was significantly lower in the 80 mg group than in the 40 mg group (p < 0.05). No severe adverse events occurred in either group, and the occurrence of adverse events did not significantly differ between them (p = 0.56).
Conclusion: Our findings do not demonstrate a direct dose-dependent renoprotective effect of telmisartan. The higher telmisartan dose resulted in a decrease in the amount of urinary protein. Even though high-dose angiotensin II receptor blockers may be preferable for patients with stage 3–4 chronic kidney disease, the clinical importance of the study results may be limited. The study was registered in the UMIN-CTR (https://www.umin.ac.jp/ctr) with the registration number UMIN000040875.

Keywords
Angiotensin receptor blocker, chronic kidney disease, renoprotection, proteinuria, telmisartan

Date received: 27 June 2020; accepted: 26 October 2020

Introduction
Renoprotective therapy, including inhibition of the renin angiotensin system (RAS), in patients with chronic kidney disease (CKD) is important to support renal function, especially in patients with overt proteinuria.1,2 Several systematic reviews have evaluated the risk of combined renal outcomes of treatment with angiotensin II receptor blockers (ARBs) in CKD patients and indicated that ARBs have a favorable effect on renal outcomes.3–6

Although diabetes is still the predominant cause of renal failure in patients undergoing hemodialysis in Japan, the
proportion of patients with nephrosclerosis has increased to nearly that of patients with chronic glomerulonephritis. According to the African American Study of Kidney Disease and Hypertension (AASK) trial, nephrosclerosis tends to be associated with a lower degree of proteinuria than diabetic nephropathy or glomerulonephritis, and the administration of RAS inhibitors to patients with nephrosclerosis has little effect on renal outcomes compared with beta-blockers or calcium channel blockers. In addition, there is a concern that lower glomerular blood pressure (BP) may be associated with reduced glomerular filtration rates in patients with nephrosclerosis, especially in elderly patients with moderate to severe CKD. Therefore, safety and efficacy should be considered when administering RAS inhibitors to CKD patients with non-nephrotic proteinuria.

It has been demonstrated that RAS inhibition by ARBs may exert renoprotective effects in a dose-dependent manner. For example, 300 mg irbesartan exerts stronger effects than 150 mg irbesartan in terms of urinary albumin excretion and overt diabetic nephropathy prevention. In these studies, none of the participants had moderate to severe renal insufficiency, such as CKD stage 3–4; only one study investigated dose-dependent renoprotection in patients with moderate to severe CKD and found a higher degree of proteinuria. Consequently, we attempted to elucidate whether ARBs exert dose-dependent renoprotective effects in patients with moderate to severe CKD and non-nephrotic proteinuria. We conducted a prospective multicenter open-label analysis to clarify the dose-dependent renoprotective effect and safety of the long-term administration of the ARB telmisartan on patients with stage 3 or 4 CKD without nephrotic level proteinuria (e.g. 3.5 g/day).

Methods

Study design

This was a multicenter, prospective, open-label, randomized control study with an inclusion period from 1 March 2009 to 29 February 2012. Participants were included if they were at least 20 years old, had stage 3–4 CKD with an estimated glomerular filtration rate (eGFR) of 15–60 mL/min/1.73 m², were receiving antihypertensive therapy, and had sustained BP control. The exclusion criteria were as follows: heavy liver dysfunction like Child-Pugh class C cirrhosis and/or poor bile secretion, possibility of pregnancy or lactation, history of hypersensitivity to telmisartan or its analogous drugs, nephrotic proteinuria (> 3.5 g/gCr), corticosteroid or immunosuppressant use within the past 6 months, acute myocardial infarction within the past 6 months, congestive heart failure, cerebral infarction, transient ischemic attack, and renal artery stenosis. After considering the eligible patients in our facilities during the period of this trial, the sample size was settled to 100. Written informed consent was obtained from all participants. All procedures involving human participants were performed in accordance with the ethical standards of the institutional and/or national research ethics committee (Nagasaki University Hospital IRB approval number 08090558-6) and the 1964 Helsinki Declaration and its amendments or comparable ethical standards. The study was registered in the UMIN-CTR (https://www.umin.ac.jp/ctr) under registration number UMIN000040875.

Patients were observed for 104 weeks, and the target BP level was less than 130/80 mm Hg. Patients with a urinary protein level of > 1 g/gCr have a target BP level of < 125/75 mm Hg, in accordance with the Japanese Society of Nephrology guidelines. Throughout the follow-up period, antihypertensive drugs were allowed as long as they were not RAS inhibitors, such as angiotensin-converting enzyme inhibitors (ACEi) or anti-aldosterone drugs.

Run-in and screening periods (4 weeks)

Four weeks before randomization, ACEi, ARBs, and direct renin inhibitors were discontinued, and the patients were prescribed 20 mg telmisartan. In fact, telmisartan was prescribed within 4 weeks before the randomization. During this period, patients with a sustained potassium level of 5.5 mEq/L under appropriate anti-hyperkalemia therapies, including diet guidance, ion exchange resin use, and metabolic acidosis adjustment, and those who experienced a 30% increase in the serum creatinine level were excluded from further analyses.

Observational period (8 weeks)

Participants were randomized 1:1 into pre-allocated block sizes (block size 4) and stratified by age (60 years and over or less), sex (male or female), and CKD stage (3 or 4) using the UMIN-INDICE system. Participants in Group A (low-dose group) received telmisartan at an up-titrated dose of 40 mg at 4 weeks, and this dose was continued for an additional 4 weeks. Participants in Group B (high-dose group) received telmisartan at an up-titrated dose of 40 mg over the first 4 weeks; thereafter, the dose was increased to 80 mg for the next 4 weeks. All participants were expected to receive nutritional guidance (salt restriction and low-protein diet) at least one time during the observational period. The study protocol is illustrated in Figure 1.

Data collection

BP, blood and urinary chemistry data (serum creatinine, eGFR, and urinary protein), history of adverse events, and patients’ backgrounds were collected at the entry of this study and again at week 0 (initiation of telmisartan) and weeks 12, 24, 52, 76, and 104. Regarding the baseline data, we divided the patients into three categories based on the amount of proteinuria, which was proposed as a substitute for the microalbuminuria categories of the CKD heat map. Specifically, a protein–creatinine ratio (PCR) < 142 mg/gCr corresponds to the albumin–creatinine ratio (ACR) stage A1, ACR < 30 mg/g, and PCR of 142–660 mg/gCr corresponds to the ACR stage 2, ACR of 30–299 mg/gCr, and
PCR > 660 mg/g corresponds to the ACR stage 3, and ACR > 300 mg/g. The eGFR was calculated according to the Japanese Society of Nephrology as $194 \times \text{Cr}^{-1.094} \times \text{age}^{-0.287}$ for men and the same value $\times 0.739$ for women.

Outcomes

The primary outcome was a composite of a doubling of the serum creatinine level, transition to CKD stage 5, end-stage renal disease onset, or death from any cause. Secondary outcomes included proteinuria and eGFR decline. Regarding the follow-up schedule, participants visited the facilities every 1–3 months.

Statistical analysis

All analyses were conducted in accordance with the intention-to-treat principle. Continuous values are shown as mean $\pm$ standard deviations and/or median $\pm$ interquartile ranges. Categorical variables are expressed as percentages. Statistical analyses, including t tests, Wilcoxon rank sum tests, and Fisher’s exact tests, were used to evaluate differences between the groups. BP, eGFR, and urinary protein excretion were analyzed by a repeated measures analysis of variance (ANOVA), and multiple comparisons were conducted when the ANOVA was significant. The event occurrence rate was evaluated using the Kaplan–Meier method and compared using a log rank test. All statistical analyses were performed using JMP 13 software (SAS Institute Inc., Cary, NC, USA). Differences with $p < 0.05$ (two-tailed) were considered statistically significant.

Results

Clinical characteristics of patients

Seventy-three patients were screened during the run-in period. Of these, 12 patients were excluded due to sustained hyperkalemia ($n = 1$), high-degree proteinuria ($n = 6$), and lost consent or dropout ($n = 5$). The remaining 61 eligible participants were randomly allocated to Group A (telmisartan 40 mg; 32 patients) and Group B (telmisartan 80 mg; 29 patients). The baseline characteristics of patients are shown in Table 1. There were no significant differences in the backgrounds of the patients between the two groups, except with regard to the serum sodium level; Group A had a higher serum sodium level than Group B ($p = 0.02$). In Group A, 27 participants completed the 104-week analysis or reached the primary outcome; in Group B, 23 participants completed the analysis or reached the primary outcome. The flow chart of patients is shown in Figure 2.

Primary outcome

This study was conducted from 2009 to 2014, and the average follow-up period was 88.6 weeks. In total, five patients in Group A reached the primary outcome: three patients reached CKD stage 5 ($\text{eGFR} < 15 \text{mL/min/1.73 m}^2$), one patient died from acute myocardial infarction, and one patient suddenly died from cardiovascular disease (etiology unknown). Furthermore, five patients reached the primary outcome in Group B: four patients reached stage 5 CKD, and one patient began hemodialysis. Overall, there was no significant difference in the primary outcomes between these two groups (renal events free rate ($p = 0.33$) and renal and death free events ($p = 0.78$)). The Kaplan–Meier curves are shown in Figure 3.

Secondary outcomes and BP

Throughout the follow-up period, there were no significant differences in mean systolic or diastolic BP between the groups ($p = 0.30$; Figure 4(a)). Furthermore, there was no significant difference between the groups in mean eGFR change ($p = 0.53$; Figure 4(b)). In contrast, Group B showed a significantly lower degree of proteinuria than Group A ($p = 0.02$), and the post hoc analyses showed that there were significant differences after 24 weeks ($p < 0.05$). When limited to patients whose proteinuria exceeded 142 mg/gCr at the baseline (Group A ($n = 24$) and Group B ($n = 18$)), there were no significant differences between the two groups ($p = 0.11$).

The changes in the urinary protein levels in both groups are shown in Figure 4(c) and Table 2.

Adverse events

In Group A, two patients died during the follow-up period as described above, but this was not thought to be directly associated with the administration of telmisartan. Two patients in Group B experienced hyperkalemia, and one suffered from taste disturbance. All three patients recovered after stopping telmisartan administration. No severe adverse events were observed throughout the follow-up period, and there was no significant difference in the occurrence of adverse events.
between the two groups. A summary of adverse events is shown in Table 3.

### Discussion

We conducted a multicenter, prospective, open-label, randomized controlled trial to elucidate the dose-dependent renoprotective effect of telmisartan in non-nephrotic proteinuria patients with moderate to severe CKD. We did not find a significant difference in the primary outcome between the low- and high-dose telmisartan groups. Among the secondary outcomes, there was no significant difference in the eGFR, but the proteinuria in the high-dose group after 24 weeks was significantly lower than that in the low-dose group. Overall, telmisartan did not improve the hard renal outcomes, such as doubling the serum creatinine level or end-stage renal disease, in this study.

There is a concern that ARBs or ACEis for CKD patients with non-nephrotic proteinuria are of no clinical benefit. The AASK trial of antihypertensive therapy showed that ramipril had a beneficial effect in patients with a urine PCR of $\leq 0.22$ but not in patients with low-degree proteinuria, suggesting that the renoprotective effect of RAS inhibitors was only applicable to patients with some degree of proteinuria (e.g. 0.22 g/gCr).8

An angiotensin II receptor blockade by ARBs depends on their dose,21 and there have been several clinical trials describing the efficacy of supramaximal doses.11-14 Clinical dosing of ARBs was determined according to their antihypertensive effect, as they were initially approved for this purpose,22

Table 1. Patient characteristics at week 0.

|                              | Group A (40 mg) | Group B (80 mg) | p value |
|------------------------------|-----------------|-----------------|---------|
| Age (years)                  | 64 ± 11         | 66 ± 12         | 0.57    |
| Male (number (%))            | 19 (59)         | 20 (69)         | 0.59    |
| Height (cm)                  | 160 ± 9         | 163 ± 11        | 0.39    |
| Body weight (kg)             | 60 ± 11         | 65 ± 12         | 0.12    |
| Body mass index              | 23 ± 3          | 24 ± 4          | 0.35    |
| Causes of renal impairment   |                 |                 |         |
| Chronic glomerulonephritis (number (%)) | 9 (28) | 12 (41)         |         |
| Diabetes (number (%))        | 2 (6)           | 3 (10)          |         |
| Nephrosclerosis (number (%)) | 13 (41)         | 9 (31)          |         |
| ADPKD (number (%))           | 1 (3)           | 1 (3)           |         |
| Unknown (number (%))         | 7 (22)          | 4 (14)          |         |
| Medical history              |                 |                 |         |
| Diabetes mellitus (number (%)) | 3 (9)    | 8 (28)          | 0.10    |
| Hyperlipidemia (number (%))  | 9 (28)          | 11 (38)         | 0.59    |
| Ischemic heart disease (number (%)) | 1 (3)     | 1 (3)          | 1.00    |
| History of stroke (number (%)) | 1 (3)    | 3 (10)          | 0.34    |
| Laboratory parameters        |                 |                 |         |
| Hb (g/dL)                    | 12.9 ± 1.4      | 13.0 ± 1.9      | 0.80    |
| BUN (mg/dL)                  | 24 ± 9          | 25 ± 11         | 0.75    |
| Creatinine (mg/dL)           | 1.49 ± 0.57     | 1.52 ± 0.61     | 0.87    |
| Na (mEq/L)                   | 141 ± 2         | 140 ± 2         | 0.02    |
| K (mEq/L)                    | 4.3 ± 0.5       | 4.5 ± 0.5       | 0.16    |
| Cl (mEq/L)                   | 106 ± 2         | 105 ± 4         | 0.12    |
| Triglyceride (mg/dL)         | 133 (84-193)    | 120 (102-187)   | 0.67    |
| LDL-cholesterol (mg/dL)      | 108 ± 27        | 105 ± 29        | 0.65    |
| eGFR (mL/min/1.73 m²)        | 38.5 ± 14.1     | 39.0 ± 15.5     | 0.89    |
| CKD stage 3 (number (%))     | 22 (69)         | 20 (69)         |         |
| CKD stage 4 (number (%))     | 10 (31)         | 9 (31)          |         |
| Proteinuria less than 142 mg/gCr (number (%)) | 8 (25) | 11 (38)        |         |
| Proteinuria 142–660 mg/gCr (number (%)) | 12 (37.5)  | 8 (28)         |         |
| Proteinuria more than 660 mg/gCr (number (%)) | 12 (37.5)  | 10 (34)        |         |

ADPKD: autosomal dominant polycystic kidney disease; Hb: hemoglobin; BUN: blood urea nitrogen; eGFR: estimated glomerular filtration rate; Na: serum sodium; K: serum potassium; Cl: serum chloride; LDL: low-density lipoprotein.

Statistical analyses were done using t tests and Wilcoxon rank sum tests.

*Median (interquartile range).*
with their anti-proteinuric effects as secondary outcomes. A previous study showed that the administration of benazepril or losartan had a dose-dependent renoprotective effect in patients with advanced proteinuric CKD (inclusion criteria: serum creatinine level of 1.5–5.0 mg/dL and urinary protein level > 1.0 g/day lasting more than 3 months) and resulted in reduced risk of hard renal outcomes. In contrast, in this study, we targeted CKD patients with non-nephrotic proteinuria. On the basis of our findings, the renoprotective effect of ARBs may be limited in this patient population.

In this study, there was no rapid decrease in the urinary protein level in the high-dose telmisartan group, but after 24 weeks, there was a significant difference in the proteinuria between the low- and high-dose groups. Reducing intraglomerular pressure by ARBs undoubtedly plays a key role in alleviating proteinuria and glomerular hypertension shortly after the administration of RAS inhibitors, but the proteinuria continuously decreased over a period of weeks to months. The precise mechanisms of lowering urinary proteins independent of intraglomerular pressure are unknown although RAS inhibition has other positive effects on the kidneys; for example, the administration of ACEi increases nephrin expression in podocytes. In addition, the overexpression of angiotensin II receptors on podocytes is associated with proteinuria through foot process effacement or the local detachment of podocytes. Furthermore, RAS inhibitors may be further developed to include reduced levels of transforming growth factor β and connective tissue growth factor and improved permselective properties of the glomerular membrane. Unless RAS inhibitors cause a rapid

Figure 2. Flow chart of patient inclusion. Flow chart was based on the CONSORT guidelines.
decline in the eGFR or unmodifiable hyperkalemia, long-term RAS inhibition would be advantageous for patients with CKD.

RAS inhibition includes some safety considerations, particularly because ARBs or ACEi for advanced CKD may increase the risk of hyperkalemia or elevated serum creatinine. In such patients, angiotensin II contracts efferent arterioles to maintain intraglomerular pressure; however, under RAS inhibition, the GFR would be reduced. Nevertheless, the renoprotective effects conferred could be tolerable and advantageous for such patients. For example, benazepril decreased the risk of renal failure by 43% in patients with serum creatinine levels of 3.1–5.0 mg/dL, without severe adverse events. A meta-analysis found that ARBs were well tolerated, and the proportion of adverse events was lower than that of the BP-lowering effect when the administration dose was increased. In this study, there were no significant differences in the occurrence of adverse events when telmisartan was administered at high or low doses, and hyperkalemia was observed only in the high-dose group. Because hyperkalemia is a life-threatening adverse event of RAS inhibition, it should not be overlooked in patients with moderate to severe CKD, especially in elderly patients.

There was no significant difference in primary outcome between the high-dose (80 mg) and the low-dose (40 mg) groups; this might have been due to the lack of statistical power in this study. We attempted to estimate a sample size for this study, but we could not perform a pilot study because of the limited number of eligible patients. In addition, when we initiated the study design, there was no appropriate study that could be used as a reference to estimate the sample size. However, the Renoprotection of Optimal Antiproteinuric Doses (ROAD) trial elucidated the dose-dependent renoprotective effect of ARB in moderate to severe CKD patients and showed that the proportion of patients in the low-dose losartan group (fixed 50 mg) who reached the primary end point was approximately 30%, whereas in the high-dose losartan group (titrated from 50 to 200 mg), the value was approximately 15% of patients in 3 years. Consequently, the risk reduction rate was approximately 50%, and 77 participants would have been needed in one arm in this study for a statistical power of 80% and a two-sided significance level of 0.05. There were several patient characteristic differences between the ROAD study and our study, such as age and etiologies of renal failure. Specifically, the patients’ backgrounds of ROAD study were as follows: the mean age was approximately 50 years old, the mean eGFR was approximately 30 mL/min/1.73 m², and the median of proteinuria was 1.4 g/day; furthermore, >50% of participants contracted glomerular disease including diabetic nephropathy. Despite the large differences between the ROAD study and ours, the results of the ROAD study suggest that our study does not seem to have enough statistical power and could not provide the anticipated results.

This study had several critical limitations. As we described above, there might have been a type II error in this study due to the small number of participants. Even though we intended to include as many participants as possible by not limiting etiologies of renal function, such as diabetes, the total number of participants was 61. This study was conducted in an open-label manner, and thus many biases may have been present. In addition, complications, etiologies for renal failure, and the level of proteinuria were not taken into consideration in the randomization. For example, the proportion of diabetes was higher in Group B (p = 0.10), and this might have affected the results. In addition, the diagnosis of nephrosclerosis was not based on renal biopsies, and we could not exclude the possibility of other etiologies. The dropout rate in both groups was approximately 10%, which may have unintentionally biased the results. Moreover, the lack of data in this study may confound the interpretation of our observations. Furthermore, there was a significant difference in
urinary protein levels between the high- and low-dose telmisartan groups after 24 weeks, but the decrease rates from baseline were not significantly different. This is because some participants had almost no proteinuria at baseline, and therefore, worsening of proteinuria could not be observed. Finally, since this study was conducted in daily clinical practice, we did not standardize instruments or the way of measuring BP. In addition, the methods used for blood chemistry and urinary examinations were not standardized among the facilities; this might have affected the results.

Table 2. Changes in urinary protein (urinary protein/urinary creatinine) over time.

|                  | Group A (40 mg) | Group B (80 mg) | p value |
|------------------|-----------------|-----------------|---------|
| Screening period | 0.78 ± 0.80     | 0.51 ± 0.60     | 0.20    |
|                  | 0.61 (0.17–1.12)| 0.27 (0.12–0.82)|         |
| Week 0           | 0.72 ± 0.70     | 0.69 ± 1.03     | 0.33    |
|                  | 0.50 (0.14–1.22)| 0.18 (0.08–0.83)|         |
| Week 12          | 0.68 ± 0.78     | 0.66 ± 1.33     | 0.26    |
|                  | 0.46 (0.11–1.00)| 0.23 (0.06–0.79)|         |
| Week 24          | 0.62 ± 0.64     | 0.45 ± 1.02     | 0.01*   |
|                  | 0.46 (0.11–0.96)| 0.08 (0.01–0.50)|         |
| Week 52          | 0.66 ± 0.69     | 0.29 ± 0.45     | 0.005** |
|                  | 0.58 (0.14–0.85)| 0.07 (0.01–0.46)|         |
| Week 76          | 0.70 ± 0.77     | 0.28 ± 0.32     | 0.04*   |
|                  | 0.41 (0.15–1.05)| 0.13 (0.05–0.44)|         |
| Week 104         | 0.71 ± 0.90     | 0.27 ± 0.36     | 0.01*   |
|                  | 0.43 (0.15–0.88)| 0.17 (0.05–0.32)|         |

Values are expressed as mean ± standard deviation and median (interquartile range).

*p < 0.05; **p < 0.01. Post hoc analyses were performed using Wilcoxon rank sum test.
Table 3. Adverse events.

|                         | Group A (40 mg) | Group B (80 mg) | p value |
|-------------------------|----------------|-----------------|---------|
| Hyperkalemia            | 0              | 2               | 0.22    |
| Taste disturbance       | 0              | 1               | 0.48    |
| Death                   | 2              | 0               | 0.49    |
| Overall                 | 2              | 3               | 0.56    |

Statistical analysis was performed using Fisher’s exact tests.

Conclusion

Our results do not clearly indicate a dose-dependent renoprotective effect of telmisartan. On the other hand, the amount of proteinuria was significantly lower in the high-dose group, without significant adverse effects, such as reduced eGFR, in either group. Since renal hard outcomes were not improved in this study, the clinical relevance of the study results may be limited.

Acknowledgements

The authors thank the participants and facilities where this study was conducted, including the Department of Nephrology Nagasaki University Hospital, Nagasaki Medical Center, Omura Municipal Hospital, Nagasaki Harbor Medical Center, Shinzato Clinic, Nagasaki Renal Center, Isahaya General Hospital, Sasebo General Hospital, Hokusho Central Hospital, St. Francisco Hospital, and Miyazaki Naika Clinic.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Ethical approval

Nagasaki University Hospital Institutional Review Board approval number 08090558-6.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

Informed consent

Written informed consent was obtained from all subjects before the study.

Trial registration

UMIN-CTR UMIN000040875. This trial was retrospectively registered. When the study design was inspected by our institutional review board (IRB) in 2008, the registration in systems was not mandatory as far as our facility, at least, and our trials were approved without UMIN-CTR registration. Our facility IRB do not approve any prospective trial without registration today. Participants data were collected through UMIN-INDICE; anonymous participants data were registered online. Both UMIN-INDICE system and UMIN-CTR are administered by University Hospital Medical Information Network (UMIN) Center, Japan.

ORCID iD

Mineaki Kitamura https://orcid.org/0000-0002-0003-8645

References

1. Remuzzi G, Perico N, Macia M, et al. The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease. *Kidney Int* 2005; 68: 57–65.
2. Praga M. Therapeutic measures in proteinuric nephropathy. *Kidney Int Suppl* 2005; 68(99): S137–S141.
3. Casas JP, Chua W, Loukogeorgakis S, et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. *Lancet* 2005; 366: 2026–2033.
4. Vejakama P, Thakkinstian A, Lerttrattananon D, et al. Renoprotective effects of renin-angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis. *Diabetologia* 2012; 55(3): 566–578.
5. Wu H-Y, Huang J-W, Lin H-J, et al. Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis. *BMJ* 2013; 347: f6008.
6. Zhao H-J, Li Y, Liu S-M, et al. Effect of calcium channels blockers and inhibitors of the renin-angiotensin system on renal outcomes and mortality in patients suffering from chronic kidney disease: systematic review and meta-analysis. *Ren Fail* 2016; 38(6): 849–856.
7. Masakane I, Nakai S, Ogata S, et al. An overview of regular dialysis treatment in Japan (as of 31 December 2013). *Ther Apher Dial* 2015; 19: 540–574.
8. Wright JT, Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. *J Am Med Assoc* 2002; 288: 2421–2431.
9. O’Hare AM, Kaufman JS, Covinsky KE, et al. Current guidelines for using angiotensin-converting enzyme inhibitors and angiotensin II-receptor antagonists in chronic kidney disease: is the evidence base relevant to older adults? *Ann Intern Med* 2009; 150: 717–724.
10. Sarafidis PA and Bakris GL. Does evidence support renin-angiotensin system blockade for slowing nephropathy progression in elderly persons? *Ann Intern Med* 2009; 150: 731–733.
11. Burgess E, Muirhead N, Rene de, Cotret P, et al. Supramaximal dose of candesartan in proteinuric renal disease. *J Am Soc Nephrol* 2009; 20(4): 893–900.
12. Schmieder RE, Klingbeil AU, Fleischmann EH, et al. Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study. *J Am Soc Nephrol* 2005; 16(10): 3038–3045.
13. Rossing K, Schjoedt JK, Jensen BR, et al. Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. *Kidney Int* 2005; 68(3): 1190–1198.
14. Aranda P, Segura J, Ruilope LM, et al. Long-term renoprotective effects of standard versus high doses of telmisartan in hypertensive nondiabetic nephropathies. *Am J Kidney Dis* 2005; 46: 1074–1079.
15. Deferrari G, Ravera M, Deferrari L, et al. Renal and cardiovascular protection in type 2 diabetes mellitus: angiotensin II receptor blockers. *J Am Soc Nephrol* 2002; 13(Suppl 3): S224–S229.

16. Hou FF, Xie D, Zhang X, et al. Renoprotection of Optimal Antiproteinuric Doses (ROAD) study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency. *J Am Soc Nephrol* 2007; 18(6): 1889–1898.

17. Evidence-based practice guideline for the treatment of CKD. *Clin Exp Nephrol* 2009; 13: 537–566.

18. Sumida K, Nadkarni G, Grams M, et al. Conversion of urine protein–creatinine ratio or urine dipstick protein to urine albumin–creatinine ratio for use in chronic kidney disease screening and prognosis: an individual participant–based meta-analysis. *Ann Intern Med* 2020; 173: 426–435.

19. Imai E, Horio M, Nitta K, et al. Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese patients with chronic kidney disease. *Clin Exp Nephrol* 2007; 11(1): 41–50.

20. Ahmed A, Jorna T and Bhandari S. Should we STOP angiotensin converting enzyme inhibitors/angiotensin receptor blockers in advanced kidney disease. *Nephron* 2016; 133(3): 147–158.

21. Forclaz A, Maillard M, Nussberger J, et al. Angiotensin II receptor blockade: is there truly a benefit of adding an ACE inhibitor. *Hypertension* 2003; 41(1): 31–36.

22. Law MR, Wald NJ, Morris JK, et al. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. *BMJ* 2003; 326: 1427.

23. Gansevoort RT, de Zeeuw D and de Jong PE. Dissociation between the course of the hemodynamic and antiproteinuric effects of angiotensin I converting enzyme inhibition. *Kidney Int* 1993; 44(3): 579–584.

24. Langham R, Kelly D, Cox A, et al. Proteinuria and the expression of the podocyte slit diaphragm protein, nephrin, in diabetic nephropathy: effects of angiotensin converting enzyme inhibition. *Diabetologia* 2002; 45(11): 1572–1576.

25. Hoffmann S, Podlich D, Hahnel B, et al. Angiotensin II type 1 receptor overexpression in podocytes induces glomerulosclerosis in transgenic rats. *J Am Soc Nephrol* 2004; 15(6): 1475–1487.

26. Andersen S, Blouch K, Bialek J, et al. Glomerular permselectivity in early stages of overt diabetic nephropathy. *Kidney Int* 2000; 58(5): 2129–2137.

27. MacIsaac RJ, Jerums G and Cooper ME. New insights into the significance of microalbuminuria. *Curr Opin Nephrol Hypertens* 2004; 13: 83–91.

28. Choudhri AH, Cleland JGF, Rowlands PC, et al. Unsuspected renal artery stenosis in peripheral vascular disease. *Br Med J* 1990; 301: 1197–1198.

29. Fan FH, Zhang X, Guo HZ, et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. *N Engl J Med* 2006; 354: 131–140.

30. Montford JR and Linas S. How dangerous is hyperkalemia? *J Am Soc Nephrol* 2017; 28: 3155–3165.

31. Turgutalp K, Bardak S, Helvaci I, et al. Community-acquired hyperkalemia in elderly patients: risk factors and clinical outcomes. *Ren Fail* 2016; 38(9): 1405–1412.